FY2024 Earnings Forecast for IQVIA Issued By Leerink Partnrs

IQVIA Holdings Inc. (NYSE:IQV) – Research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for IQVIA in a research report issued to clients and investors on Tuesday, December 10th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will earn $10.13 per share for the year, up from their previous estimate of $10.07. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2026 earnings at $12.26 EPS and FY2027 earnings at $13.70 EPS.

Other equities analysts have also issued research reports about the stock. Morgan Stanley decreased their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Robert W. Baird cut their price target on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a report on Wednesday. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $256.19.

IQVIA Stock Performance

Shares of IQV opened at $199.06 on Friday. The firm has a 50-day moving average price of $212.86 and a 200 day moving average price of $224.44. The firm has a market capitalization of $36.13 billion, a PE ratio of 26.12, a P/E/G ratio of 2.07 and a beta of 1.49. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73.

Hedge Funds Weigh In On IQVIA

Hedge funds have recently added to or reduced their stakes in the company. First Foundation Advisors grew its holdings in IQVIA by 3.8% during the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 43 shares during the last quarter. Invera Wealth Advisors LLC boosted its position in shares of IQVIA by 0.3% in the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after acquiring an additional 46 shares during the period. Private Trust Co. NA boosted its position in shares of IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 47 shares during the period. Oregon Public Employees Retirement Fund boosted its position in shares of IQVIA by 0.3% in the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after acquiring an additional 48 shares during the period. Finally, Continuum Advisory LLC boosted its position in shares of IQVIA by 3.3% in the second quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock valued at $325,000 after acquiring an additional 49 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.